Valuation: Insmed Incorporated

Market Cap 23.28B 20.48B 19.02B 17.5B 32.81B 2,255B 33.4B 227B 88.72B 1,100B 87.4B 85.51B 3,815B P/E 2026 *
-42.1x
P/E 2027 * 213x
Enterprise Value 22.72B 19.98B 18.56B 17.07B 32.02B 2,200B 32.59B 222B 86.58B 1,073B 85.29B 83.44B 3,723B EV / Sales 2026 *
13.4x
EV / Sales 2027 * 8.03x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Insmed Incorporated

1 day+0.72%
1 week-0.05%
Current month+0.74%
1 month+5.15%
3 months-25.32%
6 months-31.24%
Current year-38.28%
1 week 105.09
Extreme 105.09
109.99
1 month 101.67
Extreme 101.67
119.54
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 20.16
Extreme 20.164
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
7/9/26 Fiscal year

Chief Executive Officer

32,097 0.0148%
7/6/26 Fiscal year

Chief Technology Officer

36,906 0.0170%
6/25/26 Fiscal year

Chief Executive Officer

64,194 0.0296%
Change 5-day change 1-year change 3-year change Capi.($)
+0.72%-0.05%+3.84%+409.54% 23.28B
+1.23%+0.35%+51.62%+87.98% 55.92B
+1.33%+7.34%+63.40%+68.55% 56.67B
+0.25%+0.55%-19.67%-15.22% 23.28B
-1.43%+4.49%+29.45%-4.71% 20.54B
-0.59%+1.34%+26.06%-29.70% 17.78B
-2.21%+4.85%+31.51%+539.10% 15.9B
-2.54%-8.73%+164.11%+289.45% 14.64B
+1.22%-0.05%+22.58%+182.63% 13.99B
-2.16%+21.58%+445.10%+140.52% 12.22B
Average -0.43%+3.29%+81.80%+166.81% 25.42B
Weighted average by Cap. +0.16%+4.06%+62.31%+135.47%

Financials

2026 *2027 *
Net sales 1.7B 1.5B 1.39B 1.28B 2.4B 165B 2.44B 16.62B 6.48B 80.34B 6.39B 6.25B 279B 2.78B 2.44B 2.27B 2.09B 3.91B 269B 3.98B 27.13B 10.58B 131B 10.42B 10.2B 455B
Net income -561M -494M -459M -422M -791M -54.36B -805M -5.48B -2.14B -26.51B -2.11B -2.06B -91.98B 71.64M 63M 58.53M 53.83M 101M 6.94B 103M 700M 273M 3.38B 269M 263M 11.74B
Net Debt -563M -495M -460M -423M -793M -54.53B -808M -5.5B -2.15B -26.6B -2.11B -2.07B -92.27B -979M -861M -800M -735M -1.38B -94.77B -1.4B -9.56B -3.73B -46.22B -3.67B -3.59B -160B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-07-23 US$107.41 +0.72% 1,752,962
26-07-22 US$106.64 -1.82% 1,771,277
26-07-21 US$108.62 +1.50% 2,447,392
26-07-20 US$107.02 -1.20% 2,015,930
26-07-17 US$108.32 +0.80% 2,002,884
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
107.41USD
Average target price
196.18USD
Spread / Average Target
+82.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock